Skip to main content
. 2022 Feb 1;14:364–376. doi: 10.1016/j.bioactmat.2022.01.042

Fig. 6.

Fig. 6

In vivo immunomodulatory efforts: (a) H&E staining of the peri-implant tissues after subcutaneous implantation for 3 and 7 days with the fibrous layers marked by dashed lines; (b) Thickness of the fibrous layers around the implants (n = 6 per group); (c) Immunofluorescent staining of the peri-implant tissues after subcutaneous implantation for 3 and 7 days: red (iNOS, M1 marker), green (CD163, M2 marker) and blue (nuclei); (d) Ratios of iNOS-positive cells to CD163-positive cells in the peri-implant tissues (n = 6 per group). *p < 0.05 compared to PEEK, #p < 0.05 compared to PEEK-ALN.